Esophageal Cancer Panel Sequencing

Esophageal Cancer Panel Sequencing

Description of Esophageal Cancer

Esophageal cancer is the 8th most common cancer and 6th leading cause of cancer-related deaths in the world. The overall prognosis of esophageal cancer is poor with a 5-year survival that ranges from 15 to 25%. However, improved patient outcomes have been reported when esophageal cancer is diagnosed in its early stages. Cancers of the esophagus are primarily categorized into two subtypes: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Although the incidence of esophageal adenocarcinoma has increased rapidly, esophageal squamous cell carcinoma remains the predominant form of esophageal cancer worldwide and accounts for 80% of all cases. The accumulation of genetic alterations has a pivotal role during malignant progression of normal esophageal squamous mucosa to esophageal squamous cell carcinoma. Studies implicate a number of well-known tumor suppressor genes and oncogenes, such as TP53, CDKN2A, PIK3CA, RB1 and genes within the receptor tyrosine kinase/mitogen-activated protein kinase pathways.

To better understand the relationship between the mutation of esophageal cancer-related genes and the molecular biology mechanism of esophageal cancer, CD Genomics utilizes targeted NGS sequencing technology and offers a comprehensive library of esophageal cancer panel. If necessary, you can choose genes that fit your requirements.

Gene List of Esophageal Cancer Panel

AKT1 ATRX BRAF CDK6 CDKN2A CIC CTNNB1 DDX3X EGFR FUBP1
H3F3A HRAS IDH1 IDH2 KLF4 KRAS MET MYC MYCN NF1
NF2 NRAS PIK3CA PTCH1 PTEN RB1 SETD2 SMO TERT TP53

Highlights of Esophageal Cancer Panel Sequencing Service

  • Target-enrichment sequencing by Illumina provides extremely high depth (average depth > 1000x) with lower costs.
  • High coverage uniformity ensures the sequencing data more efficiency.
  • SNVs, indels, and even low frequency variations can be detected.
  • Strict quality control throughout the pipeline workflow to ensure the accuracy and repeatability of the sequencing.
  • Fast turnaround time.

Applications of Esophageal Cancer Panel Sequencing

  • Cancer related mechanism studies
  • Biomarker discovery
  • Therapeutic target discovery
  • Drug target discovery
  • Discover rare mutations and detect low frequency mutations

Service Specifications

Service Specifications

Sample Requirements

  • Sample types for genome DNA from tissues, whole blood, cultured cells, and formalin-fixed paraffin-embedded (FFPE) tissues.
  • Recommended amount: 2μg
  • Minimum amount: 200ng
  • Collection: DNA samples are stored in TE buffer or equivalent. Blood is collected by routine blood collection kits.
Service Specifications

Sequencing

  • Illumina PE150
  • Enrichment Method: Amplicon sequencing
  • More than 80% of bases with a ≥Q30 quality score
  • Recommended sequencing depth: ≥ 500x
Service Specifications

Bioinformatics Analysis

We provide customized bioinformatics analysis including:

  • Read alignment
  • Variant calling/Annotation

Gene Panel Workflow

CD Genomics provides the accurate and cost-effective esophageal cancer panel sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for esophageal cancer panel sequencing is outlined below.

Gene Panel Workflow

Clinical Guidance on Gene Mutation by NCCN Guideline

Gene Targeted Drugs
ERBB2 Trastuzumab

For more information about the esophageal cancer panel or need other amplification requirements, please contact us.

References:

  1. Pennathur A, et al. Oesophageal carcinoma. Lancet, 2013. 381, 400-412.
  2. Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136, 359-386.
  3. Nikiforova M N, et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol, 2016. 18, 379–387.
  4. Aatur D S, et al. Targeted next-generation sequencing supports epidermoid metaplasia of the esophagus as a precursor to esophageal squamous neoplasia. Modern Pathology, 2017. 30, 1613–1621.
* For Research Use Only. Not for use in diagnostic procedures.

Online Inquiry
  • Please input "genomics" as verification code.

  • 45-1 Ramsey Road, Shirley, NY 11967, USA
  • 1-631-275-3058 (USA)
           44-208-144-6005 (Europe)
  • 1-631-614-7828
  • info@cd-genomics.com
Copyright © 2009 - 2020 CD Genomics. All rights reserved.
0
Inquiry Basket